{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T07:24:51Z","timestamp":1740122691619,"version":"3.37.3"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T00:00:00Z","timestamp":1654819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T00:00:00Z","timestamp":1654819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1AI069412"],"award-info":[{"award-number":["UM1AI069412"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Behav"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s10461-022-03736-z","type":"journal-article","created":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T13:19:13Z","timestamp":1654867153000},"page":"4107-4114","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Sexual behavior and medication adherence in men who have sex with men participating in a pre-exposure prophylaxis study of combinations of Maraviroc, Tenofovir Disoproxil Fumarate and\/or Emtricitabine (HPTN 069\/ACTG 5305)"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7460-733X","authenticated-orcid":false,"given":"Kenneth H.","family":"Mayer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krista","family":"Yuhas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K. Rivet","family":"Amico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy","family":"Wilkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raphael J.","family":"Landovitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark A.","family":"Marzinke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig . W","family":"Hendrix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan H.","family":"Eshleman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leslie M.","family":"Cottle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheryl","family":"Marcus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wairimu","family":"Chege","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex R.","family":"Rinehart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James F.","family":"Rooney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip","family":"Andrew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert A.","family":"Salata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manya","family":"Magnus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason E.","family":"Farley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert Y.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"Frank","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Santana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanne D.","family":"Stekler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying Q.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marybeth","family":"McCauley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roy M.","family":"Gulick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"HPTN 069\/ACTG 5305 Study Team","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,10]]},"reference":[{"key":"3736_CR1","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1056\/NEJMoa1011205","volume":"363","author":"RM Grant","year":"2010","unstructured":"Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363:2587\u201399.","journal-title":"N Engl J Med"},{"key":"3736_CR2","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0140-6736(15)00056-2","volume":"387","author":"S McCormack","year":"2016","unstructured":"McCormack S, Dunn DT, Desai M, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2016;387:53\u201360.","journal-title":"Lancet"},{"key":"3736_CR3","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1056\/NEJMoa1506273","volume":"373","author":"JM Molina","year":"2015","unstructured":"Molina JM, Capitant C, Spire B, et al. On-demand pre-exposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med. 2015;373:2237\u201346.","journal-title":"N Engl J Med"},{"key":"3736_CR4","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1056\/NEJMoa1108524","volume":"367","author":"JM Baeten","year":"2012","unstructured":"Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367:399\u2013410.","journal-title":"N Engl J Med"},{"key":"3736_CR5","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1056\/NEJMoa1110711","volume":"367","author":"MC Thigpen","year":"2012","unstructured":"Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367:423\u201334.","journal-title":"N Engl J Med"},{"key":"3736_CR6","unstructured":"US Centers for Disease Control and Prevention. Recommendations for HIV prevention for adults and adolescents with HIV in the United States. Available at: https:\/\/www.cdc.gov\/hiv\/pdf\/risk\/prep\/cdc-hiv-prep-guidelines-2017.pdf. Accessed October 16, 2021."},{"key":"3736_CR7","unstructured":"World Health Organization. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. 2021. Available at: https:\/\/www.who.int\/publications\/i\/item\/9789240031593. Accessed October 16, 2021."},{"key":"3736_CR8","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1202614","volume":"367","author":"L Van Damme","year":"2012","unstructured":"Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367:411\u201322.","journal-title":"N Engl J Med"},{"key":"3736_CR9","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1056\/NEJMoa1402269","volume":"372","author":"JM Marrazzo","year":"2015","unstructured":"Marrazzo JM, Ramjee G, Richardson BA, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015;372:509\u201318.","journal-title":"N Engl J Med"},{"key":"3736_CR10","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1097\/QAD.0000000000000156","volume":"28","author":"MM Solomon","year":"2014","unstructured":"Solomon MM, Lama JR, Glidden DV, et al. Changes in renal function associated with oral emtricitabine\/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis. AIDS. 2014;28:851\u20139.","journal-title":"AIDS"},{"key":"3736_CR11","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1001\/jamainternmed.2014.6786","volume":"175","author":"KK Mugwanya","year":"2015","unstructured":"Mugwanya KK, Wyatt C, Celum C, et al. Changes in glomerular kidney function among HIV-1-uninfected men and women receiving emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis: a randomized clinical trial. JAMA Intern Med. 2015;175:246\u201354.","journal-title":"JAMA Intern Med"},{"key":"3736_CR12","doi-asserted-by":"publisher","first-page":"e90111","DOI":"10.1371\/journal.pone.0090111","volume":"9","author":"M Kasonde","year":"2014","unstructured":"Kasonde M, Niska RW, Rose C, et al. Bone mineral density changes among HIV-uninfected young adults in a randomised trial of pre-exposure prophylaxis with tenofovir-emtricitabine or placebo in Botswana. PLoS One. 2014;9:e90111.","journal-title":"PLoS One"},{"key":"3736_CR13","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1093\/cid\/civ324","volume":"61","author":"K Mulligan","year":"2015","unstructured":"Mulligan K, Glidden DV, Anderson PL, et al. Effects of emtricitabine\/tenofovir on bone mineral density in HIV-negative persons in a randomized,double-blind,placebo-controlled trial. Clin Infect Dis. 2015;61:572\u201380.","journal-title":"Clin Infect Dis"},{"key":"3736_CR14","first-page":"1211","volume":"211","author":"DA Lehman","year":"2015","unstructured":"Lehman DA, Baeten JM, McCoy CO, et al. Risk of drug resistance among persons acquiring HIV within a randomized clinical trial of single- or dual-agent preexposure prophylaxis. J Infect Dis. 2015;211:1211\u20138.","journal-title":"J Infect Dis"},{"key":"3736_CR15","doi-asserted-by":"crossref","unstructured":"Gibas KM, van den Berg P, Powell VE, Krakower DS. Drug resistance during HIV pre-exposure prophylaxis. Drugs. 2019 Apr;79(6):609\u2013619.","DOI":"10.1007\/s40265-019-01108-x"},{"key":"3736_CR16","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1056\/NEJMoa0803152","volume":"359","author":"RM Gulick","year":"2008","unstructured":"Gulick RM, Lalezari J, Goodrich J, et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med. 2008;359:1429\u201341.","journal-title":"N Engl J Med"},{"key":"3736_CR17","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at: http:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/ AdultandAdolescentGL.pdf. Accessed October 3,2021."},{"key":"3736_CR18","doi-asserted-by":"crossref","unstructured":"Brelot A, Chakrabarti LA. CCR5 revisited: How mechanisms of HIV entry govern AIDS pathogenesis. J Mol Biol. 2018 Aug 17;430(17):2557\u20132589.","DOI":"10.1016\/j.jmb.2018.06.027"},{"key":"3736_CR19","doi-asserted-by":"crossref","unstructured":"Gulick RM, Wilkin TJ, Chen YQ, et al. Phase 2 study of the safety and tolerability of maraviroc-containing regimens to prevent HIV infection in men who have sex with men (MSM) (HPTN 069\/ACTG A5305)\u201d. J Infect Dis. 2017 Jan 15;215(2):238\u2013246.","DOI":"10.1093\/infdis\/jiw525"},{"issue":"11","key":"3736_CR20","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1097\/QAD.0000000000000647","volume":"17","author":"JE Haberer","year":"2015","unstructured":"Haberer JE, Bangsberg DR, Baeten JM, et al. Defining success with HIV pre-exposure prophylaxis: a prevention-effective adherence paradigm. AIDS. 2015 Jul;17(11):1277\u201385. 29(.","journal-title":"AIDS"},{"issue":"1","key":"3736_CR21","doi-asserted-by":"publisher","first-page":"e55013","DOI":"10.1371\/journal.pone.0055013","volume":"8","author":"CW Hendrix","year":"2013","unstructured":"Hendrix CW, Chen BA, Guddera V, et al. MTN-001: randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments. PLoS ONE. 2013;8(1):e55013.","journal-title":"PLoS ONE"},{"key":"3736_CR22","doi-asserted-by":"crossref","unstructured":"Emory JF, Seserko LA, Marzinke MA. Development and bioanalytical validation of a liquid chromatographic-tandem mass spectrometric (LC-MS\/MS) method for the quantification of the CCR5 antagonist maraviroc in human plasma. Clin Chim Acta. 2014 Apr 20;431:198\u2013205.","DOI":"10.1016\/j.cca.2014.02.008"},{"issue":"1","key":"3736_CR23","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1089\/aid.2015.0182","volume":"32","author":"CW Hendrix","year":"2016","unstructured":"Hendrix CW, Andrade A, Bumpus NN, et al. Dose frequency ranging pharmacokinetic study of tenofovir-emtricitabine after directly observed dosing in healthy volunteers to establish adherence benchmarks (HPTN 066). AIDS Res Hum Retroviruses. 2016 Jan;32(1):32\u201343.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"8","key":"3736_CR24","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1093\/aje\/kwr183","volume":"15","author":"LN Yelland","year":"2011","unstructured":"Yelland LN, Salter AB, Ryan P. Performance of the modified poisson regression approach for estimating relative risks from clustered prospective data. Am J Epidemiol. 2011 Oct;15(8):984\u201392. 174(.","journal-title":"Am J Epidemiol"},{"issue":"7","key":"3736_CR25","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1056\/NEJMoa2101016","volume":"12","author":"RJ Landovitz","year":"2021","unstructured":"Landovitz RJ, Donnell D, Clement ME, et al. Cabotegravir for HIV prevention in cisgender men and transgender women. N Engl J Med. 2021 Aug;12(7):595\u2013608. 385(.","journal-title":"N Engl J Med"},{"key":"3736_CR26","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1097\/QAI.0b013e3182a7a97a","volume":"65","author":"RM Gulick","year":"2014","unstructured":"Gulick RM, Fatkenheuer G, Burnside R, et al. Five-year safety evaluation of maraviroc in HIV-1-infected treatment-experienced patients. J Acquir Immune Defic Syndr. 2014;65:78\u201381.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"3736_CR27","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1093\/cid\/civ455","volume":"61","author":"BO Taiwo","year":"2015","unstructured":"Taiwo BO, Chan ES, Fichtenbaum CJ, et al. Less bone loss with maraviroc- vs tenofovir-containing antiretroviral therapy in the AIDS clinical trials group A5303 study. Clin Infect Dis. 2015;61:1179\u201388.","journal-title":"Clin Infect Dis"},{"key":"3736_CR28","doi-asserted-by":"publisher","first-page":"384","DOI":"10.7326\/M17-0520","volume":"167","author":"RM Gulick","year":"2017","unstructured":"Gulick RM, Wilkin TJ, Chen YQ, et al. Phase 2 safety and tolerability study of maraviroc-containing regimens to prevent HIV infection in women (HPTN 069\/ACTG A5305): a randomized trial. Ann Intern Med. 2017;167:384\u201393.","journal-title":"Ann Intern Med"},{"key":"3736_CR29","doi-asserted-by":"publisher","first-page":"8952","DOI":"10.1128\/JVI.01204-13","volume":"87","author":"I Massud","year":"2013","unstructured":"Massud I, Aung W, Martin A, et al. Lack of prophylactic efficacy of oral maraviroc in macaques despite high drug concentrations in rectal tissues. J Virol. 2013;87:8952\u201361.","journal-title":"J Virol"},{"key":"3736_CR30","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1097\/QAD.0000000000000769","volume":"29","author":"J Coll","year":"2015","unstructured":"Coll J, Molto J, Boix J, et al. Single oral dose of maraviroc does not prevent ex-vivo HIV infection of rectal mucosa in HIV-1 negative human volunteers. AIDS. 2015;29:2149\u201354.","journal-title":"AIDS"},{"key":"3736_CR31","doi-asserted-by":"publisher","first-page":"R11","DOI":"10.1186\/ar3685","volume":"14","author":"DL Fleishaker","year":"2012","unstructured":"Fleishaker DL, Garcia Meijide JA, et al. Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebo-controlled trial. Arthritis Res Ther. 2012;14:R11.","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"3736_CR32","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1097\/QAI.0000000000000479","volume":"68","author":"SE Cohen","year":"2015","unstructured":"Cohen SE, Vittinghoff E, Bacon O, et al. High interest in preexposure prophylaxis among men who have sex with men at risk for HIV infection: baseline data from the US PrEP demonstration project. J Acquir Immune Defic Syndr. 2015;68(4):439\u201348.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"Suppl 1","key":"3736_CR33","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1093\/cid\/ciu266","volume":"59","author":"KR Amico","year":"2014","unstructured":"Amico KR, Stirratt MJ. Adherence to preexposure prophylaxis: current, emerging, and anticipated bases of evidence. Clin Infect Dis. 2014;59(Suppl 1):55\u201360.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"3736_CR34","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1001\/jamainternmed.2015.4683","volume":"176","author":"AY Liu","year":"2016","unstructured":"Liu AY, Cohen SE, Vittinghoff E, et al. Preexposure prophylaxis for HIV infection integrated with municipal- and community-based sexual health services. JAMA Intern Med. 2016;176(1):75\u201384.","journal-title":"JAMA Intern Med"},{"issue":"10","key":"3736_CR35","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1093\/cid\/civ778","volume":"61","author":"JE Volk","year":"2015","unstructured":"Volk JE, Marcus JL, Phengrasamy T, et al. No new HIV infections with increasing use of HIV preexposure prophylaxis in a clinical practice setting. Clin Infect Dis. 2015;61(10):1601\u20133.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"3736_CR36","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1007\/s13365-018-0716-3","volume":"25","author":"M Hoenigl","year":"2019","unstructured":"Hoenigl M, Morgan E, Franklin D, et al. Self-initiated continuation of and adherence to HIV pre-exposure prophylaxis (PrEP) after PrEP demonstration project roll-off in men who have sex with men: associations with risky decision making, impulsivity\/disinhibition, and sensation seeking. J Neurovirol. 2019 Jun;25(3):324\u201330.","journal-title":"J Neurovirol"},{"key":"3736_CR37","first-page":"597","volume":"68","author":"T Finlayson","year":"2019","unstructured":"Finlayson T, Cha S, Xia M, et al. Changes in HIV preexposure prophylaxis awareness and use among men who have sex with men\u201420 urban areas, 2014 and 2017. MMWR. 2019;68:597\u2013603.","journal-title":"MMWR"},{"key":"3736_CR38","first-page":"801","volume":"68","author":"D Kanny","year":"2019","unstructured":"Kanny D, Jeffries WL, Chapin-Bardales J, et al. Racial\/ethnic disparities in HIV preexposure prophylaxis among men who have sex with men\u201423 urban areas, 2017. MMWR. 2019;68:801\u20136.","journal-title":"MMWR"},{"key":"3736_CR39","doi-asserted-by":"crossref","unstructured":"Wu H, Mendoza MC, Huang YA, Hayes T, Smith DK, Hoover KW. Uptake of HIV preexposure prophylaxis among commercially insured persons-United States, 2010\u20132014. Clin Infect Dis. 2017 Jan 15;64(2):144\u2013149.","DOI":"10.1093\/cid\/ciw701"},{"key":"3736_CR40","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1097\/COH.0b013e3283582d4a","volume":"7","author":"KR Amico","year":"2012","unstructured":"Amico KR. Adherence to preexposure chemoprophylaxis: the behavioral bridge from efficacy to effectiveness. Curr Opin HIVAIDS. 2012;7:542\u20138.","journal-title":"Curr Opin HIVAIDS"},{"issue":"10246","key":"3736_CR41","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S0140-6736(20)31065-5","volume":"25","author":"KH Mayer","year":"2020","unstructured":"Mayer KH, Molina JM, Thompson MA, et al. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet. 2020 Jul;25(10246):239\u201354. 396(.","journal-title":"Lancet"},{"issue":"5","key":"3736_CR42","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1007\/s10461-016-1606-4","volume":"21","author":"KH Mayer","year":"2017","unstructured":"Mayer KH, Safren SA, Elsesser SA, et al. \u201cOptimizing Pre-Exposure Antiretroviral Prophylaxis Adherence in Men Who Have Sex with Men: Results of a Pilot Randomized Controlled Trial of \u201cLife-Steps for PrEP\u201d. AIDS Behav. 2017 May;21(5):1350\u201360.","journal-title":"AIDS Behav"},{"key":"3736_CR43","unstructured":"AVAC Global Advocacy for HIV Prevention. PrEP. Available at: www.avac.org\/PrEP. Accessed March 16,2022."}],"container-title":["AIDS and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10461-022-03736-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10461-022-03736-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10461-022-03736-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T17:24:35Z","timestamp":1667841875000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10461-022-03736-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,10]]},"references-count":43,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["3736"],"URL":"https:\/\/doi.org\/10.1007\/s10461-022-03736-z","relation":{},"ISSN":["1090-7165","1573-3254"],"issn-type":[{"type":"print","value":"1090-7165"},{"type":"electronic","value":"1573-3254"}],"subject":[],"published":{"date-parts":[[2022,6,10]]},"assertion":[{"value":"26 May 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Mayer has received research grant funding from Gilead Sciences and Merck, Inc, and has served on scientific advisory boards for Gilead Sciences, Merck, and ViiV.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/competing interests"}},{"value":"The protocol was approved by the Institutional Review Boards of all of the participating sites.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All participants were educated about the protocol by study staff who were trained by the HPTN for the conduct of the trial, and then reviewed an IRB approved informed consent document. If they felt that their questions were addressed and wanted to participate in the study, they then were asked to sign the document.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Study protocol prohibited the sharing of individual data. Participants agreed to allow for sharing of de-identified data with the Statistical Data Management Center of the HPTN, at the Fred Hutchinson Cancer Center.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}